Pioneering Precision Medicine: Undecimal Bio's Vision for Targeted Therapeutics
Overcoming the 'Liver Trap' in Genetic Medicine Delivery
The realm of RNA interference has brought about transformative changes in the treatment of diseases affecting the liver. However, a significant barrier has persisted: the difficulty in effectively delivering these RNA-based medicines to tissues located outside the liver. This limitation has constrained the full potential of siRNA therapeutics, confining their application primarily to liver-expressed conditions.
Introducing DELiveri®: An AI-Powered Delivery Platform
To surmount this challenge, Undecimal Bio has developed DELiveri®, an innovative AI-enabled platform. This groundbreaking technology is engineered to screen vast libraries of potential ligand conjugates, essentially reprogramming cells to act as molecular sensors. These sensors precisely detect successful therapeutic delivery at a single-molecule resolution. The extensive, high-throughput data generated from this process is then analyzed by advanced AI agents. These intelligent systems decode complex structure-activity relationships, enabling the identification of optimal conjugates capable of ferrying siRNA into designated target cells with unparalleled accuracy.
Initial Focus: Revolutionizing Renovascular Disease Treatment
Undecimal Bio is initially deploying its DELiveri platform to tackle renovascular diseases—a group of conditions characterized by a substantial unmet clinical need. Current treatments for these ailments often alleviate symptoms without addressing the root etiological factors. By leveraging targeted siRNA delivery, Undecimal Bio aims to introduce the precision of genetic medicines, offering durable and specific silencing of disease-driving pathways, thereby moving beyond symptomatic relief to curative approaches.
Strategic Funding to Accelerate Innovation and Expansion
The million seed financing round saw co-leadership from prominent venture capital firms 4BIO Capital and IQ Capital, with additional participation from Verve Ventures, Harel Tech, Entree Capital, Kerna Ventures, and Saras Capital. This capital will be strategically allocated to further enhance the DELiveri platform, accelerate the progress of Undecimal Bio's renovascular programs, and facilitate the expansion of its team at its state-of-the-art laboratories located within the Cancer Research UK Cambridge Institute.
Collaborations and Leadership Driving Future Growth
In a testament to its promising technology, Undecimal Bio has also forged several research collaborations with major pharmaceutical companies, details of which are yet to be publicly announced. The company's Board of Directors includes representatives from 4BIO Capital, IQ Capital, and Harel Technologies, alongside co-founders Dr. Yaniv Erlich and Shaul Ilan. Verve Ventures has also joined the board as an observer, further strengthening the leadership team's expertise and strategic vision.
CEO's Vision: Unlocking the Full Potential of siRNA Therapeutics
Dr. Yaniv Erlich, CEO and Co-Founder of Undecimal Bio, articulated the company's core mission: "The significant challenge in RNA interference has always been precise molecular delivery, not the silencing itself. Our DELiveri platform, which has been validated in vivo, enables us to screen vast chemical spaces at an unprecedented rate. This generates massive datasets that our AI agents meticulously decipher to uncover structure-activity relationships and pinpoint the most effective candidates. We are enthusiastic about utilizing these advancements to develop the next generation of siRNA therapeutics, ultimately benefiting patients worldwide."
